Introduction
The kidney is both a cause and a victim of hypertension. High blood pressure is a key pathogenic factor that contributes to the deterioration of kidney function. The presence of kidney disease is a common and underappreciated pre-existing medical cause of resistant hypertension. 1 Therefore, treatment of hypertension has become the most important intervention in the management of all forms of chronic kidney disease (CKD). For this reason, the forthcoming World Kidney Day on 12 March 2009 will emphasize the role of hypertension in renal disease.
How does one recognize the presence of chronic kidney disease?
In contrast to a decade ago, today most laboratories around the world report an estimated glomerular filtration rate (eGFR) instead of, or in addition to, serum creatinine. This now provides the physician with information about kidney function that is, in general, more precise. As a result, a greater percentage of patients with diabetes or hypertension, and their physicians, have a better measure of their kidney function. The assessment of eGFR as an index of kidney function should be complemented by assessing urine for protein or albumin (preferred).
In spite of these laboratory updates, recent data show that a given patient's knowledge that he or she has CKD is very low. In a recent analysis of almost half a million people in Taiwan, who took part in a standard medical screening program, 12 per cent had CKD. 2 It was noteworthy that only less than four per cent of those with CKD were aware of their condition. People with CKD are several times more likely to die from cardiovascular (CV) causes than those without CKD, thus, hypertension is a major risk factor in this context. 3 The combination of CKD and hypertension, therefore, is a major public health issue; because of the costly treatments necessary for end-stage renal disease (ESRD); end-stage CKD has also become a substantial burden to health budgets.
What is the worldwide frequency of chronic kidney disease?
The frequency of CKD continues to increase worldwide as does the prevalence of ESRD. 4, 5 The most common, but not the only, causes of CKD are hypertension and diabetes. The presence of CKD is associated with a large increase in CV risk. Moreover, CV risk increases proportionally as eGFR falls below 60 ml min À1 . Death from CV causes in CKD is much higher than that from cancer in CKD; as a result, the identification and reduction of CKD has become a public health priority. 6 The reported prevalence of CKD stages 1-4 in the most recent NHANES (national health and nutrition examination survey) between 1999 and 2006 was 26 million out of a population base of approximately 200 million. This represented US residents aged 20 years and older; of these, 65.3% had CKD stage 3 or 4. Those with diabetes and hypertension had far greater prevalence of CKD (37 and 26%, respectively) compared with those without these conditions (11 and 8%, respectively). 7 In a more recent, yet unpublished report from the CKD-surveillance group, the prevalence or amount of CKD stages [1] [2] [3] [4] in the general population increased by 30%, from 1994 to 2006.
The most recent report of the United States Renal Data System estimates that nearly half a million patients in the United States were treated for ESRD in 2004, 8 and by 2010 this figure is expected to increase by approximately 40%. Patients destined to progress to ESRD, that is, the elderly, are a growing segment of the population. In addition, males and African-Americans with pre-existing hypertension and CKD are also at a much higher risk for ESRD. 9 This observation has also been confirmed throughout the developed world: Europe, Asia, Australia and regions of India and Africa. 4, 5 The role of hypertension Hypertension is a global problem, projected to worsen. It is the major risk factor for development and progression in non-diabetic and diabetic CKD.
The world population is getting older, and ageing is the most common risk factor for the development of hypertension and diabetes, as well as CKD. Nearly one billion people worldwide have high blood pressure (defined as 4140/90 mm Hg), and that number is expected to increase to 1.56 billion by 2025. 10 The predicted prevalence of hypertension will increase by 24 per cent in developed countries and by 80 per cent in developing regions, such as Africa and Latin America. One report observed that 333 million adults in economically developed regions, such as North America and Europe, had high blood pressure in 2000, and an additional 639 million people in developing countries have this condition.
In 1999-2006, the prevalence of hypertension in US adults was 43.4% when defined as 4140/ 90 mm Hg, and similar figures have been reported from many Western countries. 9 The rates of hypertension were highest in participants who were 60 years or older, that is, 68-80% versus 25% in those between 20 and 39 years, in non-Hispanic blacks (53%) versus Caucasians (43%) versus MexicanAmericans (34%). Furthermore, hypertension was more common in individuals with a higher body mass index (BMI) (60% for BMI X35 vs 32% for BMI of 23). Slightly more than half of the adults with hypertension were aware of their disease in 1999-2004; fewer than half were treated for their hypertension with medications; and less than two-thirds were controlled to o140/90 mm Hg with medication. 9 This trend in poor blood pressure control is observed worldwide.
The hypertension control rate, defined as blood pressure o130/80 mm Hg, is substantially less in patients with CKD, particularly in those with diabetes and CKD. 1, 9 This is illustrated by the National Kidney Foundation's (USA) Kidney Early Evaluation Program (KEEP), a US-based healthscreening program for individuals at a high risk for kidney disease. 9 The prevalence (86.2%), awareness (80.2%) and treatment (70.0%) of hypertension in the screened cohort were high; however, blood pressure control rates were low (13.2%). The proportion of hypertensive patients increased with advancing stages of CKD.
Which blood pressure component is most relevant for renal and cardiovascular risk, systolic or diastolic?
There is now a consensus, based on the totality of the data, that systolic, rather than diastolic, blood pressure poses the greater risk for CV events and kidney disease progression. Against this background, it is relevant that in the KEEP study elevated systolic blood pressure accounted for the majority of patients with inadequate control. Male gender, non-Hispanic black race and BMI of X30 kg/m 2 were inversely related to blood pressure control.
What is the blood pressure target for CKD patients? According to the different guidelines published by the major kidney societies, systolic blood pressure should be lowered to values o130 mm Hg. One has to be aware, however, that as a predictor of adverse CKD or CV events, office blood pressure may be inferior compared with ambulatory blood pressure measurement. 11 This issue is particularly relevant in CKD because of the tendency for night-time blood pressure to be elevated (little or no nocturnal dip in blood pressure) and because of the fact that central (aortic) blood pressure tends to be higher than peripheral (brachial) blood pressure. 11, 12 In patients with diabetes, all guidelines recommend that lower blood pressure targets may provide further benefit, but prospective trials have, thus far, failed to confirm this epidemiological observation.
The role of diabetic nephropathy
As indicated above, diabetes and hypertension are the most common causes of CKD. There are currently over 240 million people with diabetes worldwide. This figure is projected to rise to 380 million by 2025, largely because of population growth, ageing, urbanization, unhealthy eating habits, increased body fat and a sedentary lifestyle. By 2025, the number of people with diabetes is expected to more than double in South-East Asia, the Eastern Mediterranean and Middle East, and Africa. It is projected to rise by nearly 20% in Europe, 50% in North America, 85% in South and Central America and 75% in the Western Pacific region. The top five countries with the highest prevalence of diabetes in order include India, China, the United States, Russia and Japan. Worldwide, more than 50% of people with diabetes are unaware of their condition and are not treated.
The same behaviours that increase obesity are shared with those predisposed to diabetes, that is, family history, presence of hypertension, ageing, excess body weight, lack of exercise and unhealthy dietary habits. It is important to identify these risks early to reduce the development of diabetes and CKD, as CKD greatly amplifies the risk of CV events in the diabetic patient.
The remaining challenge
Under-diagnosis and under-treatment of CKD is a worldwide problem: not only is CKD awareness low worldwide, but the relative lack of CKD risk factor awareness by physicians, that is, hypertension and diabetes, is even more disturbing. Moreover, even awareness of these risk factors does not ensure adequate treatment; this could relate either to the behaviour of the patient, the provider or both. Thus, the problem of CKD remains a challenge as exemplified by recent data showing that between 1999-2006 o5% of people with an eGFR o60 ml/min per 1.73 m 2 and proteinuria were aware of having CKD; in those with CKD stage 3, awareness was only 7.5%; in stage 4, awareness was o50%. Awareness rates among those with CKD stages 3 or 4 were higher if co-morbid diagnoses of diabetes and hypertension were present, but even then they were quite low (20 and 12%, respectively).
One barrier to overcome in order to ensure greater awareness is a more focused education of physicians, as they are the purveyors of the patients' medical condition. In one survey, more than onethird of primary care physicians in the US were not aware that family history was a risk factor for CKD, whereas almost one-quarter did not perceive African-American ethnicity as a CKD risk factor; in contrast, nearly all perceived diabetes (95%) and hypertension (97%) as risk factors for CKD. Even more problematic was the fact that although diabetes and hypertension were acknowledged as CKD risk factors, the achieved control rates (defined as reaching guideline goals) sadly remain well below 50% among those treated.
What can be done about this problem?
There have been many consensus panels over the past decade to approach ways to achieve better blood pressure control and to educate physicians on the stages of CKD. 13, 14 The road to improve outcomes is to focus on public awareness and screening programs, as well as programs to educate both patients and physicians. Data from the KEEP screening program in the US have also noted that blood pressure values are most likely to be at goal once patients are aware that they have kidney disease. 15 Data from Bolivia highlight the observation that once kidney disease is diagnosed, more appropriate interventions to reduce CKD risk factors such as hypertension are instituted. 13 Programs to address these issues have been initiated around the world including KEEP type programs. The major focus of World Kidney Day this year is hypertension in CKD (http://www.worldkidneyday. org).
Owing to the ageing world population and the consequent increase in the prevalence of hypertension and diabetes, CKD rates will continue to rise. This has and will continue to place an undue economic burden on societies, given the costs for an ESRD program. In 2005, the US spent $32 billion dollars on such programs. These facts mandate that measures be put forth to ensure the timely detection and prevention of CKD progression. The key to ensuring the successful prevention of CKD is screening for hypertension, improved testing and diagnosis of predisposing co-morbidities, such as diabetes, and aggressive treatment to guideline goals.
The International Society of Nephrology and the International Federation of Kidney Foundations have an ambitious long-term goal that worldwide, every individual, particularly the patient with diabetes, should know his or her blood pressure value. In addition, they should be aware that prompt treatment is necessary once blood pressure values are no longer in the normal range. Finally, our societies strongly encourage public health authorities to support efforts to raise public awareness of CKD, and promote moves to reduce the risk of developing hypertension. Such governmental public health initiatives are exemplified by countries such as the United Kingdom, Finland and Japan reducing salt in the diet and mandatorily labelling food items that have sodium content, as in the US. These initiatives have proven to be highly successful based on reduction in CV mortality and morbidity.
